Begin main content

Reports

We found 6261 result(s)

Buprenorphine hydrochloride (Probuphine)

Last Updated: March 22, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: buprenorphine hydrochloride
Indications: Opioid drug dependence, treatment

  • Brand Name: Probuphine
  • Manufacturer: Knight Therapeutics Inc.
  • Project Number: SR0550-000
  • Project Status: Complete
  • Submission Type: New

nusinersen (Spinraza)

Last Updated: March 26, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: nusinersen
Indications: Spinal Muscular Atrophy

  • Brand Name: Spinraza
  • Manufacturer: Biogen Canada Inc.
  • Project Number: SR0525-000
  • Project Status: Complete
  • Submission Type: New

ulipristal acetate (Fibristal)

Last Updated: April 17, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: ulipristal acetate
Indications: Uterine fibroids (signs and symptoms)

  • Brand Name: Fibristal
  • Manufacturer: Allergan Inc.
  • Project Number: SF0609-000
  • Project Status: Active
  • Submission Type: RequestForAdvice

CADTH pan-Canadian Oncology Drug Review

Published on: April 18, 2019
Result type: General Content

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process. The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces an...

CADTH Pharmaceutical Reviews Update — Issue 7

Last Updated: April 17, 2019
Result type: Reports
Product Line: Pharmaceutical Review Update

CADTH Program Updates Common Drug Review 1. Additional Embargo Period Following Revised CDEC Recommendations Effective immediately, CADTH has revised its procedures for the CADTH Common Drug Review to permit an additional embargo period for CADTH Canadian Drug Expert Committee (CDEC) recommendations that have been substantially revised following...

Pharmaceutical Reviews Update 7

Published on: April 17, 2019
Result type: News

See Pharmaceutical Reviews Update – Issue 7 for important news and information regarding CADTH’s drug review programs. This issue includes changes to the CADTH Common Drug Review procedure to include an additional embargo period for CDEC recommendations that have been substantially revised following a request for reconsideration by manufacturers...

Esketamine for Treatment-Resistant Depression

Last Updated: April 17, 2019
Result type: Reports
opens in document viewer

Major depressive disorder (MDD) is a common, debilitating, and recurrent mental health disorder. Approximately 10% to 30% of patients with MDD will not reach complete clinical remission despite multiple antidepressant pharmacologic approaches — this subpopulation is described as having treatment-resistant depression (TRD). TRD is a more chall...

  • Project Number: EH0075-000